216 related articles for article (PubMed ID: 37210688)
1. Involvement of necroptosis in the selective toxicity of the natural compound (±) gossypol on squamous skin cancer cells in vitro.
Haasler L; von Montfort C; Kondadi AK; Golombek M; Ebbert L; Wenzel CK; Stahl W; Reichert AS; Brenneisen P
Arch Toxicol; 2023 Jul; 97(7):1997-2014. PubMed ID: 37210688
[TBL] [Abstract][Full Text] [Related]
2. The BH3 mimetic (±) gossypol induces ROS-independent apoptosis and mitochondrial dysfunction in human A375 melanoma cells in vitro.
Haasler L; Kondadi AK; Tsigaras T; von Montfort C; Graf P; Stahl W; Brenneisen P
Arch Toxicol; 2021 Apr; 95(4):1349-1365. PubMed ID: 33523262
[TBL] [Abstract][Full Text] [Related]
3. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells.
Oliver CL; Bauer JA; Wolter KG; Ubell ML; Narayan A; O'Connell KM; Fisher SG; Wang S; Wu X; Ji M; Carey TE; Bradford CR
Clin Cancer Res; 2004 Nov; 10(22):7757-63. PubMed ID: 15570010
[TBL] [Abstract][Full Text] [Related]
4. (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo.
Wolter KG; Wang SJ; Henson BS; Wang S; Griffith KA; Kumar B; Chen J; Carey TE; Bradford CR; D'Silva NJ
Neoplasia; 2006 Mar; 8(3):163-72. PubMed ID: 16611409
[TBL] [Abstract][Full Text] [Related]
5. An in vitro study of cytotoxic effects of gossypol on human epidermoid larynx carcinoma cell line (HEp-2).
Konac E; Ekmekci A; Yurtcu E; Ergun MA
Exp Oncol; 2005 Mar; 27(1):81-3. PubMed ID: 15812364
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative activity of gossypol and gossypolone on human breast cancer cells.
Gilbert NE; O'Reilly JE; Chang CJ; Lin YC; Brueggemeier RW
Life Sci; 1995; 57(1):61-7. PubMed ID: 7596222
[TBL] [Abstract][Full Text] [Related]
7. New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.
Villani A; Potestio L; Fabbrocini G; Scalvenzi M
Adv Ther; 2022 Mar; 39(3):1164-1178. PubMed ID: 35089534
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of gossypol enantiomers and its quinone metabolite gossypolone in melanoma cell lines.
Blackstaffe L; Shelley MD; Fish RG
Melanoma Res; 1997 Oct; 7(5):364-72. PubMed ID: 9429219
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity studies on gossypol in tumor cell lines.
Shelley MD; Hartley L; Groundwater PW; Fish RG
Anticancer Drugs; 2000 Mar; 11(3):209-16. PubMed ID: 10831280
[TBL] [Abstract][Full Text] [Related]
10. The effect of wool hydrolysates on squamous cell carcinoma cells in vitro. Possible implications for cancer treatment.
Damps T; Laskowska AK; Kowalkowski T; Prokopowicz M; Puszko AK; Sosnowski P; Czuwara J; Konop M; Różycki K; Borkowska JK; Misicka A; Rudnicka L
PLoS One; 2017; 12(8):e0184034. PubMed ID: 28859143
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Smac, p53, and caspase pathways in induction of apoptosis by gossypol in human retinoblastoma cells.
Hsiao WT; Tsai MD; Jow GM; Tien LT; Lee YJ
Mol Vis; 2012; 18():2033-42. PubMed ID: 22876131
[TBL] [Abstract][Full Text] [Related]
12. A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells.
Tang YC; Chang HH; Chen HH; Yao JY; Chen YT; Chuang YJ; Chang JY; Kuo CC
J Food Drug Anal; 2021 Dec; 29(4):638-652. PubMed ID: 35649133
[TBL] [Abstract][Full Text] [Related]
13. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?
Ribero S; Stucci LS; Daniels GA; Borradori L
Curr Opin Oncol; 2017 Mar; 29(2):129-135. PubMed ID: 28151757
[TBL] [Abstract][Full Text] [Related]
14. Non-melanoma skin cancer: new and future synthetic drug treatments.
Amaral T; Garbe C
Expert Opin Pharmacother; 2017 May; 18(7):689-699. PubMed ID: 28414587
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
Khandelwal AR; Kent B; Hillary S; Alam MM; Ma X; Gu X; DiGiovanni J; Nathan CO
Mol Carcinog; 2019 Oct; 58(10):1715-1725. PubMed ID: 31254372
[TBL] [Abstract][Full Text] [Related]
16. Different pathways of cell killing by gossypol enantiomers.
Qiu J; Levin LR; Buck J; Reidenberg MM
Exp Biol Med (Maywood); 2002 Jun; 227(6):398-401. PubMed ID: 12037129
[TBL] [Abstract][Full Text] [Related]
17. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.
Bauer JA; Trask DK; Kumar B; Los G; Castro J; Lee JS; Chen J; Wang S; Bradford CR; Carey TE
Mol Cancer Ther; 2005 Jul; 4(7):1096-104. PubMed ID: 16020667
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines.
Coyle T; Levante S; Shetler M; Winfield J
J Neurooncol; 1994; 19(1):25-35. PubMed ID: 7815102
[TBL] [Abstract][Full Text] [Related]
19. Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer.
Zerp SF; Stoter TR; Hoebers FJ; van den Brekel MW; Dubbelman R; Kuipers GK; Lafleur MV; Slotman BJ; Verheij M
Radiat Oncol; 2015 Jul; 10():158. PubMed ID: 26223311
[TBL] [Abstract][Full Text] [Related]
20. Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines.
Shelley MD; Hartley L; Fish RG; Groundwater P; Morgan JJ; Mort D; Mason M; Evans A
Cancer Lett; 1999 Jan; 135(2):171-80. PubMed ID: 10096426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
